Yale Comprehensive Cancer Center.
Smilow Cancer Hospital at Yale-New Haven Hospital.
Clin J Oncol Nurs. 2020 Jun 1;24(3):277-283. doi: 10.1188/20.CJON.277-283.
When resection is not an option, platinum-based chemoradiotherapy (CRT) has been the historic standard of care in non-small cell lung cancer (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant improvement (versus placebo) in progression-free and overall survival in patients with unresectable stage III NSCLC without progression following CRT.
This article aims to provide an overview of the efficacy and safety outcomes with durvalumab in patients with stage III NSCLC and identify management strategies for potential adverse events (AEs).
A review of published literature and guidelines was performed to evaluate durvalumab clinical outcomes and AE management strategies.
Durvalumab has established efficacy in patients with unresectable stage III NSCLC and is now the standard of care following CRT. Nurses need to be trained to recognize potential immune-related AEs in patients treated with immune checkpoint inhibitors.
在无法进行手术的情况下，铂类化疗联合放疗（CRT）一直是非小细胞肺癌（NSCLC）的历史标准治疗方法。单独接受 CRT 的预后仍然很差。在 CRT 后无进展的不可切除 III 期 NSCLC 患者中，durvalumab 显示出在无进展生存期和总生存期方面具有显著改善（与安慰剂相比）。
本文旨在概述 durvalumab 在 III 期 NSCLC 患者中的疗效和安全性结果，并确定潜在不良反应（AE）的管理策略。
对已发表的文献和指南进行了审查，以评估 durvalumab 的临床结果和 AE 管理策略。
durvalumab 在不可切除的 III 期 NSCLC 患者中具有明确的疗效，现已成为 CRT 后的标准治疗方法。护士需要接受培训，以识别接受免疫检查点抑制剂治疗的患者中潜在的免疫相关 AE。
